Claims for Patent: 10,125,398

Summary for Patent: 10,125,398

Title:	Compositions and methods for the diagnosis and treatment of bone fractures and disorders
Abstract:	The present invention relates to the therapy, prophylaxis and diagnosis of disorders that are associated with aberrant bone mineral density, in particular osteoporosis; wherein the level of selected micro RNAs in samples of patients are detected and wherein an increase or decrease of said level compared to the level of healthy individuals is indicative of the disorder.
Inventor(s):	Grillari; Johannes (Bisamberg, AT), Grillari; Regina (Bisamberg, AT), Hackl; Matthias (Vienna, AT), Schraml; Elisabeth (Vienna, AT), Weilner; Sylvia (Perzendorf, AT)
Assignee:	UNIVERSITAT FUR BODENKULTUR WIEN (Vienna, AT)
Application Number:	15/318,646
Patent Claims:	1. A method of diagnosing and treating osteoporosis in a subject, comprising the steps of: a) providing a blood sample from said subject; b) measuring a level of hsa-miR-188-3p and at least one additional miRNA selected from the group consisting of: i) a group II miRNA selected from the group consisting of hsa-miR-127-3p, hsa-miR-143-3p, hsa-miR-214-3p, hsa-miR-30e-3p, and hsa-miR-942 or isoforms or variants thereof; and ii) a group m miRNA selected from the group consisting of hsa-miR-106b-5p, hsa-miR-141-3p, hsa-miR-19b-3p, hsa-miR-21-3p, hsa-miR-375, hsa-miR-486-3p, and hsa-miR-532-3p, or isoforms or variants thereof; c) comparing the levels of said miRNAs with the levels of corresponding miRNAs in a reference blood sample from a healthy individual; and d) when the levels of said miRNAs are higher or lower than the levels of corresponding miRNAs in a reference blood sample from a healthy individual, then treating the subject for osteoporosis by administering to the subject a composition selected from the group consisting of teriparatide, denosumab, blosozumab, romosozumab, a bisphonate, and a bone growth factor. 2. The method of claim 1, wherein there is a difference of more than one standard deviation in the levels of the miRNAs in the blood sample from the subject compared to the levels of the miRNAs in the reference blood sample. 3. The method of claim 1, wherein the levels of at least 4 miRNAs are measured. 4. The method of claim 1, wherein the levels of all of the miRNAs of group II and/or group III are measured. 5. The method of claim 1, further comprising the step of measuring levels of hsa-miR-106a-5p, hsa-miR-133b, hsa-miR-18a-3p, hsa-miR-196b-5p, hsa-miR-199b-5p, hsa-miR-200b-3p, hsa-miR-203a, hsa-miR-20b-5p, hsa-miR-323a-3p, hsa-miR-330-3p, hsa-miR-369-3p, hsa-miR-376c-3p, hsa-miR-378a-5p, hsa-miR-454-3p, hsa-miR-500a-5p, hsa-miR-550a-5p, hsa-miR-941, and hsa-miR-942. 6. The method of claim 1, wherein one or more further miRNAs are detected, wherein said miRNAs are: a) differentially regulated in osteoporotic individuals as compared to healthy individuals, and b) involved in osteogenic differentiation and/or in osteoclastogenic activation. 7. The method of claim 6, wherein said further miRNAs are group V miRNAs selected from the group consisting of hsa-miR-140-5p, hsa-miR-146a-5p, hsa-hsa-miR-199a-5p, hsa-miR-20a, hsa-miR-200a, hsa-miR-217, hsa-miR-218, hsa-miR-26a, hsa-miR-27a, hsa-miR-2861, hsa-miR-29a-3p, hsa-miR-29b-3p, hsa-miR-29c-3p, hsa-miR-204-5p, hsa-miR-335-5p, hsa-miR-34c, hsa-miR-370-3p, hsa-miR-3960 and hsa-miR-503-5p, or isoforms and variants thereof. 8. The method of claim 1, further comprising the step of performing a bone imaging procedure on the subject in order to identify whether the subject has a bone fracture. 9. The method of claim 1, wherein the subject is a osteoporosis or osteopenia patient suffering from or at risk of developing bone fractures, or is a patient at risk of or suffering from type 2 diabetes mellitus. 10. The method of claim 1, wherein the difference in miRNA levels is determined by quantitative or digital PCR, sequencing, microarray, Luminex nucleic acid assays, or other hybridization-based techniques. 11. The method of claim 1, wherein the subject is treated if there is a difference of more than 1.5 fold in the levels of said miRNAs in the blood sample from the subject when compared to the levels of the miRNAs in the reference blood sample. 12. The method of claim 1, wherein the bisphonate is alendronate or zolendronate. 13. The method of claim 1, wherein the bone growth factor is BMP-2 or BMP-7.

Details for Patent 10,125,398

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen, Inc.	PROLIA	denosumab	Injection	125320	06/01/2010		2034-06-13
Amgen, Inc.	XGEVA	denosumab	Injection	125320	11/18/2010		2034-06-13